Over the last decade there has been a substantial increase in the number of new bone graft substitutes available to the orthopaedic surgeon to assist with bone healing. Despite this, autologous graft is still considered to be the best, providing the three core elements required for bone growth (osteoconduction, osteoinduction and osteogenesis).
Over the last decade there has been a substantial increase in the number of new bone graft substitutes available to the orthopaedic surgeon to assist with bone healing. Despite this, autologous graft is still considered to be the best, providing the three core elements required for bone growth (osteoconduction, osteoinduction and osteogenesis). 1 Osteoconduction is the provision of a physical structure with a surface whose biocompatibility supports the migration of cells, such as mesenchymal lineage cells, onto it. Osteoinduction is the ability of the graft to allow the recruitment of host mesenchymal stem cells. It is widely accepted that autogenous bone is osteoinductive, owing at least in part to intrinsic bone matrix proteins such as those of the transforming growth factor (TGF)-β superfamily, which includes the bone morphogenetic proteins (BMP). Osteogenesis is the synthesis of new bone from cells within the graft that can survive in a host environment; the viability of cells in nonvascularised autografts is not known. [1] [2] [3] A fundamental disadvantage of autograft is donor site morbidity. Harvesting, commonly from the iliac crest, is considered a safe procedure, but can result in chronic pain, superficial infection, haematoma, and lesions to the lateral femoral cutaneous nerve leading to paraesthesiae and disturbances of gait. [4] [5] [6] Extremely rare complications include pelvic fracture, peritonitis and arterial injury. 7, 8 The morbidity associated with the harvesting and the finite supply of this tissue has resulted in a search for synthetic materials as an alternative.
Allograft bone has been widely used and is an attractive alternative as it avoids donor site morbidity. Osteo-arthritic femoral heads removed at total hip replacement are the predominant source of allograft bone in the United Kingdom, 9 and remain the mainstay of grafts used in revision arthroplasty surgery. However, allograft material has the potential to transmit infectious diseases and can cause an immuno-rejection reaction. 2 Excluding tissue after serological testing for human immunodeficiency virus (HIV-1 and HIV-2), hepatitis B and C, syphilis and human T-cell lymphotropic virus (HTLV-1 and HTLV2) has reduced the rate of transmission of these pathogens via allograft bone. 1, 2, 10 Other laboratory methods used to reduce the transmission of disease include the processing of allograft material. Allograft bone is available in frozen and freeze-dried forms. Storing allograft at -80°C minimises the degradation of graft and also reduces its immunogenicity. 1 Freeze-dried allograft also resists degradation when vacuum packed at room temperature. 1 Both frozen and freeze-dried forms of allograft retain their osteoconductive characteristics, although freeze-drying reduces the mechanical and osteoinductive properties of the graft. Allograft sterilisation using ethylene oxide, gamma-irradiation or thermal heat treatment can be performed to further improve its safety. All three processes, however, reduce the mechanical integrity and the osteoinductive capabilities of the graft. 2 Current methods of allograft sterilisation are ineffective against THE BONE & JOINT JOURNAL prion proteins, including variant Creutzfeldt-Jakob disease, raising the possibility of iatrogenic transmission via the allograft. 10 However, Grafton (Osteotech Ltd, Christchurch, United Kingdom) is one demineralised bone matrix that claims to be prion free. The manufacturers state that prion proteins are only associated with neural tissue and as the procurement of bone in Grafton originates solely from long bones, the final demineralised protein is prion free, eliminating the transmission of prion-related disease. 11 Many bone graft substitutes are currently commercially available in the United Kingdom, but peer-reviewed clinical evidence of their efficacy is limited. The aim of this review was to highlight the main properties of the range of bone graft substitutes, give the levels of evidence for their use, and indicate the trauma and elective procedures in which they have been used.
Materials and Methods
In order to complement our literature review, a total of 17 manufacturers of bone graft substitutes were contacted and asked to provide product details, unit costs and supporting peer-reviewed clinical literature of their efficacy. Our review of the literature included papers that detailed the use of a bone graft substitute in an orthopaedic situation. We excluded papers in neuro-and maxillofacial surgery and those not published in English. The ISI Web of Knowledge, PubMed, EMBASE (from 1980 to 2012) and Cochrane databases were searched in December 2012 using the criteria 'registered or trademarked product name', the boolean search term 'AND', plus the word 'bone'. Conference abstracts, in vitro and animal studies were excluded. Full-text peer-reviewed papers were obtained and graded according to the 'levels of evidence' introduced by Wright, Swiontkowski and Heckman 12 (Table I) . Level I evidence is a prospective randomised controlled trial (RCT) with definitive results to support the use of the bone graft substitute in a clinical setting, whereas single case reports were assigned as Level V evidence. All authors reviewed each paper and assigned a level of evidence independently. If there was disagreement on the level assigned to a paper, this was discussed and resolved. All papers with a level of evidence of I, II or III were included and referenced, as well as selected Level IV studies when they included case series of > 15 patients. All Level V studies were excluded. Osteoinductive growth factors such as the BMPs were excluded because they are a clearly defined pharmaceutical product.
Results
A total of 59 bone graft substitutes marketed by 17 different companies were identified on sale in the United Kingdom, but only 22 (37%) from 12 manufacturers met our inclusion criteria for published peer-reviewed clinical literature. A total of 96 clinical papers for these products were found. Figure 1 outlines the methodological process used to locate them. The levels of evidence are summarised in Tables II to VIII. 13 -102 We wrote to all 17 companies to verify our literature search but only six replied. The available information regarding the porosity, biomechanical strength, size, price and rates of resorption of each substitute is shown in Tables II to VIII. Some companies supplied unit costs for each product, which should be viewed as approximations as prices are subject to change. All the grafts are osteoconductive and act as a scaffold to maintain space during bone healing and ingrowth, and the demineralised bone matrices in particular have some additional osteoinductivity. Recommended indications for the clinical use of each product are also listed in Tables II to VIII. Not all RCTs were awarded Level I evidence, as many had poor methodology. After critical appraisal of the literature only five papers from four products, Alpha-BSM (DePuy, Leeds, United Kingdom), Cortoss (Orthovita, St Albans, United Kingdom), Norian SRS (Synthes, Welwyn Garden City, United Kingdom) and Vitoss (Orthovita), were considered to have Level I published data equal to or superior to autograft.
13-17
Types of bone graft substitute. Demineralised bone matrix (DBM). DBM is generally prepared into a putty or paste by removing calcium phosphate by acid extraction, and is thus composed of collagen, non-collagenous proteins and glycoproteins, including osteoinductive BMPs, which can promote the formation of bone. DBMs have limited porosity and mechanical strength; they can be safely used as a bone graft extender in spinal and trauma surgery, with good clinical results. 47, 50, 53, 55 Calcium phosphate and hydroxyapatite. Calcium phosphate cement is a white powder that consists of a combination of tricalcium phosphate (TCP), calcium carbonate and monocalcium phosphate. When mixed with water it forms a paste that can be shaped to any bone defect. It hardens quickly at physiological pH and the reaction is isothermic, thereby eliminating any risk of thermal damage to the surrounding bone. The hardening reaction forms a hydroxyapatite or apatite-like material that has a compressive strength equal to or greater than that of cancellous bone after 48 hours. The differing combinations of the three calcium materials affect the Three studies were excluded after obtaining the full-text articles as it was not clear from the abstract how many participants were involved in the study. Each of the three articles excluded had < 15 patients enrolled Flow diagram of the systematic review process.
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compressive and tensile strength of the cement. The compressive strengths of these materials are high, ranging from 10 to 100 MPa, whereas the tensile strengths are much weaker at 1 to 10 MPa. 1, 2, 10 There is a broad range of applications for this material, including filling of cranial burr holes and craniofacial reconstructive surgery (BoneSource; Stryker, Newbury, United Kingdom), and in orthopaedic surgery where load is shared with an implant (Norian SRS; Synthes). These materials are slow to remodel and can be considered permanent. Norian SRS has the most peer-reviewed literature with accompanying Level I evidence. 13, 59, 61, [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] Preformed granules and blocks of calcium phosphate are composed of tricalcium phosphate and/or hydroxyapatite. They are manufactured using a high-temperature sintering process to produce a material with a highly crystalline structure and interconnecting porosity similar to bone. A minimum pore size of 200 μm is considered optimal for bone ingrowth, whereas pore sizes > 400 μm greatly improve the formation of osteoid. 103 Pore interconnectivity is extremely important, as a closed pore structure severely impairs the penetration of ingrowing bone with its associated vasculature.
Hydroxyapatite can be produced from marine coral exoskeletons that are hydrothermally converted to hydroxyapatite, the natural mineral composition of bone. The interconnected porous structure closely resembles the porosity of human cancellous bone. Little has been published about the use of pure hydroxyapatite bone graft substitutes, and clinical trials are required to assess their efficacy. Calcium sulphate. Calcium sulphate is a biocompatible osteoconductive bone graft substitute that is resorbable and steadily substituted for new bone by 12 weeks. 104 Clinical indications include the filling of bone voids, the treatment of benign bone lesions, and the expansion of grafts often used in spinal fusion. Calcium sulphate products should not be used to fill metaphyseal defects resulting from intraarticular fractures or in load-bearing applications, as the fast resorption time may result in loss of strength before fracture healing, leading to bone collapse.
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Bioactive glass. Bioactive glasses are biocompatible products composed of silicate, calcium and phosphorus, and are both osteoinductive and osteoconductive. 106 By varying the proportions of silicon oxide, silicon dioxide and calcium oxide, different bioactive glass products, whose solubility varies from completely soluble to non-resorbable, can be manufactured. The porosity of the products provides a scaffold that allows new bone deposition after vascular Table I ) § NA, data not available ingrowth and osteoblastic differentiation.
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A strong bond formed by hydroxyapatite crystals is created between bone and the bioactive glass without an intervening connective tissue interface, which gives it good apposition to bone. After long-term implantation the bioactive glass is partially replaced by bone. 107, 108 Cortoss (Orthovita) contains bioactive glass and has been successfully used in kyphoplasty and vertebroplasty as well as spinal fusion.
43-45
Collagen and collagen/HA. Collagen is an osteoconductive material and when used alone provides minimal structural support as a bone graft substitute, which limits its use clinically. However, it can be used as a carrier for growth and bone differentiation factors, especially BMPs. 106 Collagen can be combined with other osteoconductive materials, such as hydroxyapatite or tricalcium phosphate, as well as osteoinductive bone marrow aspirate. 109 Vitoss (Orthovita) is one such product that combines type 1 collagen with * TCP, tricalcium phosphate; DBM, demineralised bone matrix † HA, hydroxyapatite ‡ OC, osteoconductive; OI, osteoinductive § PRP, platelet-rich plasma ¶ n, number of peer-reviewed papers describing clinical use of the registered or trade-marked product; Level of evidence denoted I to IV (see Table  I ) **NA, data not available spinal fusion when supplemented by appropriate fixation. 18, 19 Actifuse has currently not been cleared for use in vertebroplasty. It has recently been shown that magnesium ions enable the hydroxyapatite crystal cell structure to become unstable and more biologically active, thereby promoting rapid cellmediated material resorption, new bone formation and remodelling. The inclusion of magnesium in the hydroxyapatite improves its interaction with water, further stimulating osteogenesis. 36 SINTlife (JRI Orthopaedics, London, United Kingdom) is a magnesium-substituted hydroxyapatite that is resorbed over a period of six to 18 months, allowing time for the formation and maturation of new bone. Clinical indications are as a bone-void filler in trauma, knee and spinal surgery. A recent small RCT showed promising results using SINTlife in the treatment of medial compartment osteoarthritis of the knee treated with a high tibial osteotomy supplemented with internal fixation, when it was compared with the use of lyophilised bone chips. 36 There is some evidence for the use of bone graft substitutes in tibial plateau fractures, distal radial fractures, calcaneal fractures and spinal surgery.
Indications for use of bone graft substitute. Tibial plateau fractures. Buttress plating and elevation of a depressed articular surface leaves a contained metaphyseal void that should heal but this runs the risk that the subchondral surface will collapse. Autologous bone graft is commonly packed into the defect but it lacks the mechanical stability to allow early weight-bearing. Alternative substitutes that can be used are the calcium cements, which can be injected into the void and offer improved stability and strength, allowing early weightbearing. Jubel et al 69 performed a prospective study looking at the use of injectable Norian SRS cement in 21 tibial plateau fractures to supplement internal fixation. The mean follow-up was 30 months. Full weight-bearing was achieved after a mean of 3.7 weeks, with clinical and radiographic results comparable to those following the use of autologous graft. They tibial plateau fractures. A total of 120 closed unstable tibial plateau fractures were enrolled in this prospective trial involving 12 centres in the United States. The range of movement of the knee was higher in the Alpha-BSM group than in the autograft group at six and 12 months, and radiologically there was a significantly higher rate of articular subsidence in the autograft group than in the Alpha-BSM group after one year. There were no major complications and the authors supported the use of Alpha-BSM in the management of tibial plateau fractures. showed that anatomical outcome was improved when using cement compared with plaster cast treatment alone, although there was no statistically significant difference in functional outcome, there were some concerns regarding extraosseous deposition of the cement. Cassidy et al 13 performed a randomised trial involving 323 patients with distal radial fractures, treating them either with closed reduction and percutaneous injection of Norian SRS cement, closed reduction alone, or external fixation. Significant clinical differences were seen at six to eight weeks' follow-up, with better grip strength, range of movement, reduced swelling and social function when using the Norian SRS compared to the control group (p < 0.05). However, at 12 months there were no clinical differences between the groups. Zimmerman et al 82 Table I ) § NA, data not available compared Kirschner (K)-wire fixation alone with K-wire fixation and Norian SRS in unstable distal radial fractures in 52 osteoporotic women. At a follow-up of two years, patients treated with Norian SRS had better function with improved grip strength than those treated with K-wire fixation alone (p < 0.001). Jakubietz et al 65 performed an RCT in which 20 patients were randomised to be treated with a dorsal plate (Pi-Plate; Synthes) and ChronOS (Synthes) bone graft substitute and 19 were randomised to be treated with a dorsal plate alone. All patients were aged > 50 years and had a closed AO type C 111 distal radial fracture. The authors used ChronOS granules to fill the defects remaining after reduction of the fracture and stabilisation with the Pi-Plate. Post-operative treatment regimes were identical for both groups. All fractures were united by 12 weeks and there was no statistical difference in radiological and clinical outcomes between the two groups. Most RCTs involving distal radial fractures and bone graft substitutes include different treatment regimes and multiple fracture patterns, ranging from AO type A2 to C3. Jakubietz et al 65 showed no benefit of ChronOS on AO type C fractures when used in conjunction with the dorsal Pi-Plate.
Norian SRS has also been used successfully in the treatment of malunited distal radial fractures when combined with a radial osteotomy. Abramo et al 84 reviewed 25 consecutive Table I ) ¶ NA, data not available patients with a dorsally malunited distal radial fracture treated with a radial osteotomy and Norian SRS and found statistically significant improvements in movement, grip strength and Disabilities of the Arm, Shoulder and Hand (DASH) scores.
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In one case the cement had fragmented before bony union, with failure of fixation at two months. * DBM, demineralised bone matrix; TCP, tricalcium phosphate; † BMP, bone morphogenetic protein; IGF, insulin-like growth factor; TGF, transforming growth factor ‡ OC, osteoconductive; OI, osteoinductive § n, number of peer-reviewed papers describing clinical use of the registered or trade-marked product; Level of evidence denoted I to IV (see Table I 79 Johal et al 14 conducted an RCT involving closed fractures of the calcaneum. A total of 24 fractures were treated by ORIF and Alpha-BSM, a calcium phosphate, and 28 by ORIF alone. Although there was a difference in the mean reduction of Bohler's angle in both groups one year postoperatively (6.2° in the ORIF and Alpha-BSM group vs 10.4° in the ORIF alone group; p = 0.05), there was no difference in the Short-Form (SF)-36 113 and Oral Analog Scale (OAS) scores 114, 115 between the two groups. Thordarson and Kuehn 34 used demineralised bone matrix to stimulate fusion of the ankle or hindfoot. A total of 37 patients were treated with Grafton putty (Osteotech) and five (14%) developed a nonunion; 26 were treated with Orthoblast (Isotic Orthobiologics, Irvine, California) and two (8%) developed a nonunion. There were no statistical differences between the two groups. Rates of nonunion ranging from 5% to 30% continue to be reported for ankle or hindfoot fusions without bone graft substitutes. 116, 117 Spinal surgery. Autologous bone graft is often used to supplement healing in spinal surgery. A recent multicentre prospective study by Cammisa et al 47 included 120 patients in whom autograft bone was implanted on one side of the spine and a mixture of Grafton and iliac bone graft on the contralateral side. Fusion rates of 52% were seen on the Grafton/autograft side compared to 54% on the autograft side. Grafton may thus be useful in spinal fusion, as less graft needs to be harvested from the iliac crest to produce similar rates of fusion.
Balloon kyphoplasty has significantly improved the outcome after vertebral compression fractures. A recent RCT by Blattert et al 66 compared the use of Norian SRS with polymethylmethacrylate (PMMA) in balloon kyphoplasty. A total of 60 AO type A osteoporotic vertebral fractures were included, and Norian SRS or PMMA was injected into 30 randomised vertebrae each. The authors concluded that Norian SRS performed well in AO type A1.3 osteoporotic vertebral fractures; however, in more complex AO type 3 fractures, significant failure of this cement was seen. The authors and the manufacturers do not recommend the use of Norian SRS in the treatment of AO type 3 fractures by balloon kyphoplasty, favouring the use of PMMA for all osteoporotic vertebal fractures.
Lerner et al 15 conducted an RCT with a mean follow-up of four years comparing Vitoss (Orthovita), a Beta TCP, to autograft in the posterior instrumented correction of adolescent idiopathic scoliosis. Two groups of 20 patients received either iliac crest autograft or Vitoss to supplement fusion. In the Vitoss group all patients except one had radiological fusion at the final follow-up. Four patients in the autograft group had persistent donor site pain at four years.
There was no difference in the pain scores and the correction of the curves between the groups. A limitation of that study is that 17 patients underwent thoracoplasty, with the resected rib used as supplementary graft. Nine patients in the Vitoss group and eight in the autograft group had supplementary rib autograft, thereby introducing a systematic error into the study. However, the study supports use of Vitoss in posterior instrumented fusion in patients with adolescent idiopathic scoliosis.
Ploumis et al 30 performed a case-control study comparing Healos (a collagen-hydroxyapatite bone graft substitute; DePuy) with bone marrow aspirate and autograft (n = 12) to cancellous allograft and autograft (n = 16) in patients with degenerative lumbar scoliosis undergoing posterolateral fusion. Similar function and visual analogue pain scores were seen in both groups; however, the Healos, bone marrow aspirate and autograft group had a significantly slower rate of fusion than the allograft and autograft group (mean 10.9 months vs 8 months; p < 0.05). The reduction in Cobb angle at two years was similar in both groups. The authors recommended the use of Healos when limited sources of autograft were available. at one year, with no further progression. No patient had radiolucent lines involving all three zones and no patient required revision surgery. The authors were unclear about the significance of the early development of the radiolucent lines and these patients remain under review. The study, however, supports the use of a mixture of Apapore 60 and allograft in complex acetabular surgery. Study quality. Five RCTs were considered to be Level I evidence and the results showed that the substitutes were equal or superior to autograft. [13] [14] [15] [16] [17] Four were multicentre studies conducted in the United States, 13, 14, 16, 17 and the study by Lerner et al 15 was performed at one centre in Germany. Both studies involving Alpha-BSM (DePuy) declared funding from industry, whereas the studies using Norian SRS (Synthes), Cortoss (Orthovita) and Vitoss (Orthovita) did not. Three studies reported the method of random sequence generation 14, 16, 17 but only three recorded the process of allocation concealment, two with the use of sealed envelopes 15, 16 and the other using an independent worker pulling consective tabs.
14 Inclusion and exclusion criteria were reported in four studies. 13, 14, 16, 17 Four studies had no differences in the baseline characteristics of the patients; however, the study by Cassidy et al 13 had a significant gender difference between the groups, which may have introduced bias. A sample-size calculation was conducted in three studies, as well as the reporting of a primary outcome measure. 13, 14, 17 No study had any post-randomisation exclusion criteria, which is a strength. The overall percentage of patients that completed the follow-up ranged from 75% to 95% in all studies and this was regarded as excellent. The two studies involving Alpha-BSM reported the use of blinded radiographers to score the post-operative radiographs. Alpha-BSM is a radiodense calcium phosphate material and therefore it would be impossible to blind the assessors when scoring the radiographs, which is a weakness.
14,16

Discussion
The reconstruction of large bony defects created during trauma or revision arthroplasty surgery is a major concern for orthopaedic surgeons. Over the last decade many new bone graft substitutes have become available. However, despite many in vitro and in vivo studies in animals, few clinical data are available to justify their use. Currently, many products are licensed for use in the axial skeleton without any published literature regarding their safety or long-term outcome. This is the largest review on bone graft substitutes, with 59 products from 17 manufacturers being considered. The summaries in Tables II to VIII will assist surgeons when choosing a product for a specific situation. Using three observers to assign each paper a level of evidence increases the validity of the study. However, it has limitations. First, the bone graft substitutes were searched using their product name in multiple databases, and some papers might have been missed if they did not specify which product had been used. Second, we only considered papers in English, and clearly papers are available for some products in other languages.
All 59 products have osteoconductive properties, with porosity, pore size and degradation potential being important factors when choosing which to use. Regeneration of bone is facilitated by angiogenesis and porosity, with optimal pore sizes being between 200 μm and 500 μm. Bioresorbability is facilitated by the microporosity of the graft, and pore sizes < 5 μm are essential for degradation of the graft substitute. 119, 120 The rate of resorption varies between the products and are dependent on their composition. Calcium phosphate cements are degraded by osteoclastic activity within two years. 121 Calcium sulphate cements are usually resorbed within two or three months, which limits their use as a bone graft substitute, and they are not suitable for cases where structural support is required. Sintered hydroxyapatite resists degradation and can remain in bone for more than ten years. 121 All the bone graft substitutes are currently available in the United Kingdom, and their clinical indications are listed in Tables II to VIII . A large cortical void cannot be reconstructed using a bone graft substitute without additional structural support. Four substitutes have Level I data for orthopaedic surgery. Norian SRS has been used to treat fractures of the tibial plateau, calcaneum, distal radius and proximal femur with good results when supplemented by additional fixation. 13, [59] [60] [61] [62] 66, [68] [69] [70] [71] [72] [73] [74] [75] [76] [78] [79] [80] Vitoss and Cortoss have been used as an alternative to PMMA in the treatment of vertebral fractures, with promising results. 15, 17, [37] [38] [39] 42, 44, 45 Alpha-BSM has been used to treat tibial plateau fractures, with excellent results. 14, 16 It is to be hoped that in future newer compounds will be incorporated into the grafts to make a composite material that is easier to mix and handle. Currently most grafts consist of a liquid and a powder that are mixed to create an injectable paste. Pre-mixed injectable bone substitutes are being made that are easier to use but have a slightly lower tensile strength. Recent work has looked at reinforcement of the graft by the addition of fibres to improve the elastic modulus and tensile strength. 122 The addition of chitosan, a linear polysaccharide, improves flexibility, tensile strength and elastic modulus, which allows the paste to be moulded into any shape without compromising its strength. 122, 123 One area of continuing research is the incorporation of antibiotics into bone graft substitutes. Many experimental studies are being undertaken, and Rupprecht et al 124 reported good results in the treatment of mandibular nonunions treated with Targobone (Ossacur AG, Oberstenfeld, Germany), a bovine collagen compound that includes teicoplanin.
Cost is a major consideration: harvesting an iliac crest graft costs approximately £400 in our hospital, without taking into account the cost of the increased morbidity. An allograft femoral head weighing approximately 40 to 60 g costs £700. Where available, the cost of the product is given in Tables II to VIII; all are more expensive than allograft. They are, however, sterile, easily stored and immediately available for use.
Regulation of the use of bone graft substitutes is essential in order to prevent harm to patients. Before a substitute is licensed for clinical use, there should be a requirement that clinical data be published and reviewed by the regulatory agencies. Thompson et al 125 have highlighted the shortcomings of the current system for approval of medical devices in the United Kingdom. The authors recommend that a public record is created every time a manufacturer approaches a notified body for approval of a new bone graft substitute or implant, and information on whether a product has previously been turned down by any other regulatory bodies should be made available. Although the European Commission is revising the regulation of medical devices, these changes are not expected to take effect until at least 2015. Currently, manufacturers are only required to submit information gathered from similar, equivalent products.
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Thus a new bone graft substitute may be used worldwide, without evidence of its safety and performance. We recommend that all data for currently available bone graft substitutes should be published to allow surgeons and patients to make more informed decisions regarding their use.
In conclusion, little information is currently available about the safety and performance of new bone graft substitutes: only four products, Alpha-BSM (DePuy), Cortoss (Orthovita), Norian SRS (Synthes) and Vitoss (Orthovita) have Level I published data showing that their use gives the same as or better results than autograft. Further RCTs and clinical trials are essential to assess the clinical efficacy of these products in orthopaedic surgery. Surgeons using these products must be aware of the limited data that are available, and improved medical regulation of these products based on clinical evidence must be sought.
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